This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways
by Zacks Equity Research
Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways
Add These 5 Stocks With Solid Sales Growth to Your Portfolio
by Swayta Shah
Consistent growth in sales is the key to survival for any business.
ResMed (RMD) Rides on Strong SaaS Growth & New Product Suite
by Zacks Equity Research
ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.
ResMed (RMD) Up 7.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed Study Shows Remote Monitoring Benefits on CPAP Use
by Zacks Equity Research
Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
ResMed (RMD) continues to see strong sales from SaaS business as well as new mask products and devices.
ResMed's (RMD) Q3 Earnings Beat Estimates, Revenues in Line
by Zacks Equity Research
ResMed (RMD) registers double-digit global revenue growth in Q3 on the back of solid sales from Software-as-a-Service businesses and new mask products plus devices.
ResMed (RMD) Q3 Earnings Surpass Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 5.95% and -0.19%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ResMed (RMD) Q3 Earnings Expected to Decline
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed Launches AirFit P30i Nasal Pillows Mask in the US
by Zacks Equity Research
ResMed (RMD) to expand its portfolio of sleep apnea devices on the back of AirFit P30i nasal pillows mask.
ResMed's Brightree Widens ReSupply Solution Usage for HME
by Zacks Equity Research
Resmed's (RMD) Brightree ReSupply is a scalable and automated solution that comprises live-agent inbound and outbound calls for more private interaction with patients and email reminder capabilities.
ResMed's (RMD) Brightree Unveils Analytics Platform for HME
by Zacks Equity Research
The Analytics arm, launched by ResMed (RMD) unit Brightree, provides workflow insights and facilitates KPI tracking plus peer benchmarking without the users having to amass the data themselves.
ResMed (RMD) Rides on International Growth & Innovation
by Zacks Equity Research
We expect ResMed's (RMD) new product menu and strategies to gain traction from the sleep-disordered breathing market and further drive its near-term performance.
Walgreens Boots (WBA) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
A difficult macroeconomic environment and market challenges made the fiscal second quarter the toughest since the formation of Walgreens Boots Alliance (WBA).
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) is currently keeping well with its goals to strengthen foothold in the multi-billion gene sequencing market.
Here's Why You Should Invest in ResMed (RMD) Stock Right Now
by Zacks Equity Research
ResMed (RMD) continues to invest and expand presence in high-growth markets like China, South Korea, India, Brazil and many countries in Eastern Europe.
ResMed (RMD) Introduces ReSupply Solution, Expands in HME
by Zacks Equity Research
ResMed (RMD) claims ReSupply solution to improve patient response through growth in the long-term therapy adherence of those suffering sleep apnea.
ResMed's New Brightree Suite to Boost Home Infusion Business
by Zacks Equity Research
ResMed's (RMD) Brightree suite upgrade will help uplift business operations by easily meeting compliance needs and offering the best quality patient care.
Resmed (RMD) to Acquire HB Healthcare to Treat Sleep Apnea
by Zacks Equity Research
ResMed (RMD) to expand in CPAP and respiratory care market in Korea.
ResMed Inks Deal With PharMerica on Medication Management
by Zacks Equity Research
The deal between ResMed's (RMD) MatrixCare and PharMerica covers NCPDP (National Council for Prescription Drug Programs) Bidirectional ePrescribing with all MatrixCare customer facilities.
Why Is ResMed (RMD) Down 13.7% Since Last Earnings Report?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates
by Zacks Equity Research
ResMed (RMD) benefits from growth at CER across all geographies. However, device sales in France and Japan get affected.
Alphabet ECG Feature OK'd by FDA, Healthcare Plans on Track
by Zacks Equity Research
Alphabet's (GOOGL) Verily scores FDA clearance for its electrocardiogram technology (ECG) in its Study Watch.
ISRG, RMD Earnings on Jan 24: Here Are the Key Predictions
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical space.
ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio
by Zacks Equity Research
ResMed's (RMD) AirFit N30i with a top-of-head connection keeps tubing out of the wearers' way, thus letting them conveniently move and sleep in any position.